Celltrion Group has successfully sold the Asia-Pacific (APAC) “Primary Care” business rights, which it acquired from multinational pharmaceutical company Takeda Pharmaceuticals (hereafter Takeda) in 2020, after three years.On Jan. 18, Celltrion concluded a contract with Dong-A Pharmaceutical for the
Daewoong Pharmaceutical announced on Dec. 1 that it has signed a contract to export Enavogliflozin, a SGLT-2 inhibitor, to a total of six countries in Russia and the Commonwealth of Independent States (CIS) region in association with the Russian pharmaceutical company JSC Pharmasyntez. The contract,
Chong Kun Dang announced on Nov. 6 that it has entered into a technology export agreement with Novartis worth US$1.305 billion for its new drug candidate CKD-510.Under the agreement, Novartis obtains exclusive rights outside of South Korea for the development and commercialization of CKD-510, a low-
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Hanmi Pharm delivered consensus-beating OP of W57.5bn for 3Q23, helped by both a higher drug (manufactured by Hanmi) sales portion at Hanmi (non-consolidated) and decreased Beijing Hanmi SG&A expense
Nine merger and acquisition (M&A) deals worth more than US$1 billion were made in the global pharmaceutical and bio industries in the first half of this year.According to the Korea Biotechnology Industry Organization (KBIO) on July 2, the global pharmaceutical and bio industries recorded nine M&A de
American global healthcare company Medtronic has announced on May 25 that it has entered a main contract to acquire EOFlow, the developer of the wearable insulin pump EOPatch.The total acquisition amount is expected to reach $738 million (approximately 971 billion won). Medtronic plans to acquire al
The Life Science Division of LG Chem is expected to rack up 1.2 trillion won (US$915 million) in sales this year backed by the growth of the Chronic Disease Department and the Special Disease Department.The Life Science Division’s sales for 2022 are estimated at 910 billion won (US$694 million) on a
Daewoong Pharmaceutical announced on Feb. 24 that it has signed a contract to export Envlo, an SGLT2 inhibitor-type diabetes drug, to Brazil and Mexico, the largest markets in Central and South America.Starting with this export contract, Daewoong Pharmaceutical will actively penetrate the global mar
POSCO International's pharmaceutical business in Sudan is generating profits while at the same time contributing to improving people's health in the African country.General Medicines Co. (GMC) in Sudan, a joint venture between POSCO International and Shinpoong Pharmaceutical, posted operatin
EOFlow Co. announced on Feb. 14 that GulfDrug LLC of the United Arab Emirates (UAE), its partner in the Gulf region, launched its tubeless, wearable, and disposable insulin pump “EOPatch” in the UAE.Beginning in February 2023, it becomes possible in the UAE to control and manage insulin infusions wi
EOFlow Co., a provider of wearable drug delivery systems, has partnered with Diabeloop, a French company developing diabetes automated treatment solutions, to provide patients with convenient access to EOFlow’s EOPatch system combined with an automated insulin delivery (AID) system.EOFlow and Diabel
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Daewoong’s 4Q22 OP is projected at W28.6bn, below consensus. In 4Q22, OPM likely narrowed on higher R&D and Pexuclu marketing expenses. Despite won depreciation, 4Q22 Nabota sales are projected at W4
EOFlow Co., a provider of wearable drug delivery systems (DDS), announced on Dec. 27 that it submitted a 510(k) application to the U.S. FDA for its wearable disposable insulin pump EOPatch.EOFlow plans to enter the U.S., the world’s largest diabetes market, with its current disposable wearable insul
Dong-A ST announced on Nov. 9 that it has attracted US$32.3 million in investment from NeuroBo Pharmaceuticals under a technology licensing-out and equity investment deal with the U.S. company.In September, Dong-A ST transferred to NeuroBo its exclusive worldwide development and sales rights for DA-
EOFlow Co. announced on Oct. 25 that it has received certification from the Ministry of Health of Indonesia to commercialize its wearable insulin pump ‘EOPatch’ and its controller ‘ADM’. Its smartphone app ‘Narsha’ does not require an approval from the ministry.On December 2021, EOFlow announced tha
EOFlow Co., the producer of EOPatch, a small and light wearable insulin pump, has exported an EOPatch production line to its joint venture in China, Sinoflow Co., the company announced on Oct. 17.On Sept. 30, the company shipped equipment to set up an EOPatch production line in Sinoflow, along with
EOFlow Co., a provider of wearable drug delivery solutions, announced on Sept. 23 that its European exclusive distributing partner A. Menarini Diagnostics showcased its tubeless, wearable, and disposable insulin pump “EOPatch” at the annual meeting of the European Association for the Study of Diabet
Dong-A ST announced on Sept. 15 that it has signed a global license-out and equity investment contract with NeuroBo Pharmaceuticals of the United States on Sept. 14.Dong-A ST has licensed out DA-1241, a treatment for type 2 diabetes and nonalcoholic steatohepatitis, and DA-1726, a treatment for obes
EOFlow Co., a provider of wearable drug delivery solutions, announced on Aug. 31 that it has received certification from the United Arab Emirate (UAE) Ministry of Health and Prevention (MOHAP) to commercialize its wearable insulin pump ‘EOPatch’ and its controller ‘ADM’ as well as its smartphone app
EOFlow Co., a provider of wearable drug delivery solutions, announced on Aug. 12 that its European partner, A. Menarini Diagnostics (‘Menarini’) will officially launch its tubeless, wearable, and disposable insulin pump “EOPatch” in Europe on Sept. 1, 2022.EOPatch is one of the only two fully dispos